Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image

Saad Zafar Usmani

Saad Zafar Usmani

Saad Zafar Usmani
University of Arkansas for Medical Sciences, USA

Biography

Saad Zafar Usmani, M.D., FACP is an Assistant Professor of Medicine at the University of Arkansas for Medical Sciences (UAMS) and also serves as the Director of Developmental Therapeutics at the Myeloma Institute for Research and Therapy at UAMS.Dr. Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed the Internal Medicine Residency at the Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a Combined Fellowship in Hematology & Medical Oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr. Usmani’s clinical interest involves hematologic malignancies and stem cell transplantation. His academic focus is on research in the biology, pathogenesis and therapy of plasma cell disorders, with specific focus on clinical/translational investigations in high-risk myeloma (genomically-defined poor risk,plasma cell leukemia, extra-medullary disease, etc.).He is on the editorial review board of numerous medical journals, and has presented extensively at national and international meetings. Dr. Usmani is a member of the SWOG Myeloma & Imaging Committees, International Myeloma Working Group, American College of Physicians, American Society of Hematology, the American Society of Clinical Oncology and the American Association for Cancer Research.

Research Interest

Clinical interest involves hematologic malignancies and stem cell transplantation. Academic focus is on research in the biology, pathogenesis and therapy of plasma cell disorders, with specific focus on clinical/translational investigations in high-risk myeloma (genomically-defined poor risk, plasma cell leukemia, extra-medullary disease, etc.)